or Try an Advanced Search...

    Technical Analysis for HUGE - FSD Pharma Inc. - Class B Subordinate Voting Shares

    Grade Last Price % Change Price Change
    F 0.14 -15.43% -0.03
    HUGE closed down 15.43 percent on Monday, July 1, 2024, on 3.27 times normal volume. The bears made the stock sink to a new 52-week low. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.
    Earnings due: Jul 18
    *** please verify all earnings dates ***
    0 Watchers
    Watchlist Portfolio

    Trend Table & Recent EOD Trading Signals

    ADX Long Term Intermediate Term Short Term
    Very Strong Down Down Down
    Historical HUGE trend table...
    Date Alert Name Type % Chg
    New 52 Week Closing Low Bearish 0.00%
    Volume Surge Other 0.00%
    New 52 Week Low Weakness 0.00%
    Wide Bands Range Expansion 0.00%
    Down 3 Days in a Row Weakness 0.00%
    Oversold Stochastic Weakness 0.00%
    New 52 Week Closing Low Bearish -15.43%
    Reversal New Lows Setup Bearish Swing Setup -15.43%
    Volume Surge Other -15.43%
    New 52 Week Low Weakness -15.43%
    Older End-of-Day Signals for HUGE ...

       Recent Intraday Alerts

    Alert Time
    2x Volume Pace about 9 hours ago
    1.5x Volume Pace about 9 hours ago
    3x Volume Pace about 9 hours ago
    Down 5% about 9 hours ago
    Down 3% about 9 hours ago
    View Earlier Intraday Alerts

    Get a Trading Assistant

    Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
    Track My Stocks
    Configure default chart indicators
    HUGE Chart by TradingView
    Basic chart:

    Profile

    FSD Pharma Inc., through its subsidiary, FV Pharma Inc., produces medical cannabis in Canada. The company focuses on the development of indoor grown pharmaceutical grade cannabis; and research and development of various cannabinoid-based treatments for central nervous system disorders and autoimmune diseases of the skin, GI tract, and musculoskeletal system, such as chronic pain. FSD Pharma Inc. has strategic alliance agreements with SciCann Therapeutics Inc., CannTab Therapeutics, and Solarvest BioEnergy Inc. The company was founded in 1998 and is headquartered in Cobourg, Canada.
    Classification
    Sector: Healthcare
    Industry: Drug Manufacturers - Specialty & Generic
    Keywords: Medicine Health Sciences Autoimmune Disease Cannabis Chronic Pain Central Nervous System Disorders Nervous System Disorders Medical Cannabis Bioenergy Cannabis In Canada Cannabinoid Skeletal System Antiemetics Antioxidants Musculoskeletal System

    Is HUGE a Buy, Sell or Hold?

    Indicator Bull Case Neutral / Hold Bear Case
    50 DMA
    200 DMA
    ADX Trend
    Oversold / Overbought
    Relative Strength
    Counts: 0 bullish, 4 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.

    Recent News

    Date Title
    Jun 28 FSD Pharma provides Corporate Update
    Jun 28 Update: FSD Pharma $2 Million Arbitration Award Upheld by Federal Court Against Former CEO
    Jun 28 FSD Pharma, Inc. Wins Final Judgment to Confirm Arbitration Award of $3,059,998 Plus Interest Entered Against Dr. Raza Bokhari, Currently Serving as Chairman and CEO of Medicus Pharma Ltd.
    Jun 27 FSD Pharma Receives Ethics Committee Approval for a Phase-1 Multiple Ascending Doses Clinical Trial for Lucid-21-302 (Lucid-MS) in Australia
    Jun 4 FSD Pharma Receives Institutional Review Board Approval to Study the Safety and Efficacy of Unbuzzd(TM) in Acute Alcohol Intoxication
    May 28 FSD Pharma Submits a Clinical Trial Protocol to Study the Safety and Efficacy of Unbuzzd(TM) in Acute Alcohol Intoxication
    May 24 FSD Pharma Provides Corporate Update
    May 16 FSD Pharma Provides Update on Celly Nu's New Packaging for unbuzzd(TM)
    May 7 FSD Pharma Submits a Phase-1 Multiple Ascending Doses Clinical Trial Application for Lucid-21-302 (Lucid-MS) for Ethics Committee Review in Australia
    Apr 30 FSD Pharma Signs Agreement with Applied Science and Performance Institute (ASPI) to Conduct a Clinical Trial in the United States to Assess the Safety and Efficacy of unbuzzd(TM) in an Induced State of Alcohol Intoxication
    See more HUGE news...

    Comments

    View full discussion...

    Indicators

    Indicator Value
    52 Week High 1.6799
    52 Week Low 0.1318
    Average Volume 1,241,195
    200-Day Moving Average 0.80
    50-Day Moving Average 0.31
    20-Day Moving Average 0.21
    10-Day Moving Average 0.18
    Average True Range 0.03
    RSI (14) 21.26
    ADX 55.46
    +DI 5.84
    -DI 29.97
    Chandelier Exit (Long, 3 ATRs) 0.24
    Chandelier Exit (Short, 3 ATRs) 0.23
    Upper Bollinger Bands 0.29
    Lower Bollinger Band 0.13
    Percent B (%b) 0.04
    BandWidth 75.50
    MACD Line -0.05
    MACD Signal Line -0.05
    MACD Histogram 0.0004
    Fundamentals Value
    Market Cap 5.39 Million
    Num Shares 39.4 Million
    EPS -0.58
    Price-to-Earnings (P/E) Ratio -0.24
    Price-to-Sales 91.86
    Price-to-Book 2.28
    PEG Ratio 0.00
    Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
    Resistance 4 (R4) 0.18
    Resistance 3 (R3) 0.18 0.17 0.17
    Resistance 2 (R2) 0.17 0.16 0.17 0.17
    Resistance 1 (R1) 0.15 0.15 0.15 0.15 0.17
    Pivot Point 0.14 0.14 0.14 0.14 0.14
    Support 1 (S1) 0.13 0.13 0.12 0.12 0.11
    Support 2 (S2) 0.11 0.13 0.11 0.10
    Support 3 (S3) 0.10 0.11 0.10
    Support 4 (S4) 0.09